N/A N=46 The Effects of an Antioxidant Formulation on Ocular Blood Flow
Primary Open Angle Glaucoma
Primary: Change in Superior Retinal Capillary Blood Flow (% Zero Pixels) — -0.026; 0.011 % zero pixels — p=0.0016
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=5 Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With Adverse Events During NKAE Treatment — 2 participants
Phase 4 N=52 Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy
Partial Epilepsy
Primary: Change in Epworth Sleepiness Scale Score From Baseline to Visit 4 — -1.2; -1.1 Units on a scale — p=0.027
Phase 3 N=10 Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Cystic Fibrosis
Primary: Part A: Observed Plasma Concentration of Lumacaftor (LUM) and Ivacaftor (IVA) at Hour 4 Post-dose (C4h) on Day 1 — 15200; 1920 nanogram per milliliter (ng/mL)
N/A N=1,125 Attain Performa(TM) Quadripolar Lead Study
Heart Failure
Primary: Lead Complication-free Rate at 6 Months — 96.04; 98.75; 96.21 Survival Probability (%)
Phase 3 N=150 TRIAD - Treatment of Insomnia and Depression
Sleep Initiation and Maintenance Disorders · Depression
Primary: Percent of Participants With Depression Remission — 36.0; 43.8 percentage of participants in arm
Phase 2 N=44 Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
Opioid-Related Disorders
Primary: Subjective Opioid Withdrawal Scale Score (SOWS) — 16; 4; 24 units on a scale
Phase 3 N=41 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
Scleroderma, Systemic · Scleroderma, Diffuse · Scleroderma, Limited
Primary: Digital Skin Microvascular Blood Flow Measured by Laser Doppler Imaging (LDI) Before Cold Stimulus — 260.0; 246.3 perfusion units
Phase 1 N=38 Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)
Non-small Cell Lung Cancer
Primary: Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Strongly PD-L1 Positive Participants — 27.3 Percentage of…
N/A N=225 A Safety and Effectiveness Study of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement
Subjects Desiring Lip Augmentation
Primary: Change From Baseline in Evaluating Investigator's Assessment of Lip Fullness on a 5-Point Scale — 1.2; 1.1; 1.1; 1.0 Scores on a Scale
Phase 3 N=108 Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Epilepsy
Primary: Adverse Events — 126; 26 Number of adverse events
N/A N=148 ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000
Heart Valve Diseases
Primary: Thromboembolism/Thrombosis — 0; 2.7; 2.4; 1.5 percentage of participants/patient-year
Phase 3 N=66 BAX 855 Pediatric Study
Hemophilia A
Primary: Number of Participants With Inhibitory Antibodies to Factor VIII (FVIII) — 0; 0; 0 participants
Phase 3 N=147 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
MDS
Primary: Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period — 59.2; 36.1 percentage of participants — p=0.008
Phase 2 N=33 Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
Recurrent Prostate Cancer
Primary: Patients With PSA <4 ng/mL at the End of the Study — 17 participants